chidamide + decitabine + anti-PD-1 antibody

This drug regimen is a **combination therapy** consisting of **chidamide** (a histone deacetylase inhibitor), **decitabine** (a DNA methyltransferase inhibitor), and an **anti-PD-1 antibody** (most often camrelizumab, but the anti-PD-1 could be another agent in different studies). This triplet targets epigenetic modulation and immune checkpoint inhibition to treat various malignancies, particularly in patients who are refractory to prior anti-PD-1 or anti-PD-L1 therapy. - **Chidamide** inhibits histone deacetylase (HDAC), reprogramming tumor and immune cell gene expression, enhancing immune recognition, and making tumor cells more susceptible to immune attack. - **Decitabine** blocks DNA methyltransferase 1 (DNMT1), increasing tumor antigen expression and upregulating HLA molecules, helping restore tumor immunogenicity and potentially overcoming resistance to immune checkpoint inhibitors. - **Anti-PD-1 antibodies** (like camrelizumab) block the interaction between PD-1 and PD-L1, releasing T cells from inhibitory signaling and promoting anti-tumor immune responses. Recent clinical trials, especially in **relapsed/refractory classical Hodgkin lymphoma (cHL)**, have demonstrated that this triplet produces robust objective response rates, including in patients who had progressed on prior anti-PD-1/decitabine therapy. The regimen is being developed for patients ineligible for, or refusing, transplant in cHL, and may also be under investigation for other lymphomas and solid tumors[2][4][5][6][9][10].

Brand names

Epidaza

Other names

chidamide + decitabine + anti-PD-1 antibodyCDP regimen